In 2003, a biological containment system for human IL-10-producing L. lactis[12] showed to be safe and improved the disease when tested in CD patients in phase I clinical trials [13]; however, clinical results did not reveal a statistically significant difference in mucosal healing between patients receiving the recombinant strains and placebo. The gene discussed is IL10; the disease is Cowden disease.